Reblozyl

Reblozyl is a medicine used to treat anaemia (low levels of red blood cells) in adults with the following blood disorders: - myelodysplastic syndromes, a group of conditions where too few blood cells are produced by the bone marrow. Reblozyl is used in patients who need regular blood transfusions and who have a very low to moderate risk of their condition developing into acute myeloid leukaemia (a blood cancer); - beta thalassaemia, a genetic condition in which patients cannot make enough beta globin, a component of haemoglobin (the protein in red blood cells that carries oxygen around the body). These diseases are rare, and Reblozyl was designated an ‘orphan medicine’ (a medicine used in rare diseases). Further information on the orphan designations can be found on ( [myelodysplastic syndromes](/en/medicines/human/orphan-designations/eu-3-14-1331): 22 August 2014; [beta thalassaemia](https://data.ec.europa.eu/ewp/media/f8bd6c6d-3535-49cd-999e-3cc2b4755999): 29 July 2014). The medicine contains the active substance luspatercept.